Logo Istituto Affiliato

IOR

An institute

affiliated to USI

Research Associate (100%) in the Cancer Immunotherapy Group

Institute of Oncology Research

The Institute of Oncology Research (IOR) in Bellinzona, Switzerland, is a rapidly evolving, leading center for basic and translational research in oncology in Europe.

IOR is affiliated to the Università della Svizzera italiana (USI) and its Faculty of Biomedical Sciences, as well as to other leading Swiss Universities and Research Centers.

The IOR is located in a brand-new, high-tech research building that hosts about 20 different research groups, with state-of-the-art labs and facilities, multicultural environment and daily occasions of interaction with world leaders in the fields of cancer, basic immunology and cancer immunology.

Together with the Institute for Research in Biomedicine (IRB), the IOR is member of Bios+, a recently established non-profit association aiming to promote, support and coordinate scientific research and teaching activities of its members (biosplus.ch).

 

Project background

The Cancer Immunotherapy Group directed by Dr. Arianna Calcinotto works on dissecting the interactions between tumour cells, the tissue-specific bacteria and the tumour-infiltrating immune cells in breast cancer initiation, progression, and treatment-resistance to develop novel effective therapies for the treatment of hormone-dependent breast cancer patients and prevention in individuals with germline BRCA mutations.

Dr. Calcinotto published more than 20 articles in peer-reviewed journals, such as Nature, Science and Nature communications (e.g., Calcinotto et al., Nature, 2018; Calcinotto et al., Nature comm, 2018; Pernigoni et al., Science, 2021; Montopoli et al., Annals of Oncol 2021; Grioni et al., Blood Adv 2021).

The Cancer Immunotherapy Lab offers a brand-new fully equipped space of 90m2 and an international, stimulating, dynamic and friendly atmosphere.

We are now looking for a motivated and enthusiastic

 

Research Associate

 

Job Description

We seek a highly motivated postdoctoral fellow interested in studying the role of tissue-microbiota and immune responses in breast cancer. Additionally, the successful candidate will be part of an ongoing effort to elucidate the mechanisms of immature myeloid cells differentiation in cancer and their role in highly proliferative hormone-dependent breast cancers.

 

Candidate’s profile

  • A highly motivated applicant with a PhD or MD/PhD degree and a strong background in cancer research and immunology
  • Familiar with cell culture and molecular biology
  • Experience in flow cytometry and mouse experimentation is mandatory
  • Excited to work in a fast-growing lab and highly collaborative environment
  • Capable of independent thinking, focused on discovery and dedicated to perform research of the highest quality
  • A team player with excellent communication and writing skills (English)

Employment

The position is located at the Institute of Oncology Research, a leading institution in basic and translational cancer research in Southern Switzerland with state-of-the-art core facilities and competitive salaries.

The position is fully funded by a Pierre Mercier Foundation grant.

Initial appointment: 1 year - 100%

 

Application

We are looking forward to receiving your comprehensive digital application in English in a single PDF-File. Application will include curriculum vitae (with training, working experience and publications), two reference letters or contact details of referees, and a statement of research interest (maximum one page).

 

Please submit your application to: humanresources@ior.usi.ch

Reference in the email object: yoursurname_AC_RA-2022

Applications sent to different contacts, in other formats or after the deadline will not be considered.

 

More information about the Institute and Dr. Arianna Calcinotto is available at following link: www.ior.usi.ch

For inquiry regarding this job please contact: arianna.calcinotto@ior.usi.ch

 

Deadline

31.08.2022

 

Starting date

Fall 2022 (date upon agreement)